MARKET

PMN

PMN

Promis Neuroscie
NASDAQ
9.34
+0.10
+1.08%
After Hours: 9.24 -0.1 -1.07% 16:41 12/16 EST
OPEN
9.14
PREV CLOSE
9.24
HIGH
9.42
LOW
9.02
VOLUME
18.06K
TURNOVER
--
52 WEEK HIGH
39.75
52 WEEK LOW
6.27
MARKET CAP
20.10M
P/E (TTM)
-0.5017
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PMN last week (1208-1212)?
Weekly Report · 1d ago
ProMIS Highlights Alzheimer's & Dementia Publication Linking Preferential Targeting Of Soluble Toxic Aβ Oligomers To Efficacy And Lower ARIA Risk
Benzinga · 6d ago
ProMIS Neurosciences announces publication highlighting PMN310
TipRanks · 6d ago
ProMIS Neurosciences Advances PMN310 Alzheimer’s Trial With Interim Results Expected in 2026
Reuters · 6d ago
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Barchart · 6d ago
After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance
NASDAQ · 12/09 05:04
ProMIS Neurosciences: Buy Rating Backed by Innovative EpiSelect™ Platform and Promising PMN310 Candidate
TipRanks · 12/08 11:55
Weekly Report: what happened at PMN last week (1201-1205)?
Weekly Report · 12/08 09:03
More
About PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Webull offers Promis Neurosciences Inc stock information, including NASDAQ: PMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PMN stock methods without spending real money on the virtual paper trading platform.